ASX RELEASE

21 March 2017

Paradigm Biopharma to present at the AusBiotech Global Investment Series in Singapore and Hong Kong

Paradigm Biopharmaceuticals Ltd (ASX:PAR) is pleased to announce that Director and CEO, Paul Rennie, will this week present at the Singapore Biotech Invest and Hong Kong Biotech Invest events.

The events are part of the 2017 AusBiotech Global Investment Series and connect life science investors with biotech and medtech innovators from across the globe. They will be held on 21 – 22 of March and 23 – 24 March, respectively.

The presentation will provide updates on the Company's drug repurposing strategy as well as its treatments for hay fever, bone marrow edema (BME) and viral arthritis. A copy of the presentation is available on the Company's website: http://www.paradigmbiopharma.com/investors/presentations.

The Company will also be meeting with other investor groups whilst in Singapore and Hong Kong.

FOR FURTHER INFORMATION PLEASE CONTACT:

Paul Rennie
Director & CEO
Paradigm BioPharmaceuticals Ltd
Level 2, 517 Flinders Lane, Melb, VIC, 3000, AUSTRALIA
ABN: 94 169 346 963
Web: http://paradigmbiopharma.com/
Email: prennie@paradigmbiopharma.com
Mobile International: +61 437 778 300
Mobile (Australia): 0437 778 300